Skip to main content
Signal8
Launch Terminal

Immatics N.V. (IMTX)

Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or 8 in solid tumor patients; IMA202, which targets melanoma-associated antigen 1 across various solid tumor types, such as squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203, aimed at preferentially expressed antigen in melanoma in adult patients with recurrent or treatment-resistant solid tumors. Additionally, IMA204, currently in preclinical stages, focuses on targeting tumor stroma cells. In its preclinical TCR Bispecifics pipeline, Immatics is advancing IMA401, which targets cancer testis antigens for solid tumor indications, and IMA402, also under investigation for solid tumor therapies. Other programs include IMA101 for cancer treatment and IMA301, an allogeneic cellular therapy candidate. Immatics has established strategic partnerships to bolster its development efforts. These include collaborations with GlaxoSmithKline Intellectual Property Development Limited for novel adoptive cell therapies across various cancer indications; MD Anderson Cancer Center for multiple T-cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC for additional novel adoptive cell therapies; and Genmab A/S to develop T-cell engaging bispecific immunotherapies for diverse cancer indications. The company's headquarters are situated in Tübingen, Germany.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Immatics N.V. logo

Immatics N.V.

NASDAQ:IMTXHealthcare
-1.50%$7.20
AH$7.20+0.00%vs close
Mkt Cap$1.1B
Float114.91M
O/S152.23M
Vol
$ Vol
RVOL
Inst Own65.6%
SI3.3%
Earnings
Dilution
Immatics N.V. logoNASDAQ:IMTX$7.20-1.50%
Upcoming Catalysts
  • IMA402READOUT
    Cash runway at this date: 4mo
    2027~60w8-K
  • IMA402READOUT
    Cash runway at this date: 18mo
    Oct 24, 20269d ago8-K
  • IMA203CD8READOUT
    Cash runway at this date: 18mo
    Oct 24, 20269d ago8-K
Phase Distribution
14 lead-sponsored trials·5 active·8 completed
Phase 17
Phase 1/23
Phase 21
Phase 32
Not applicable1
(4 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Completed

    IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma

    Sunitinib, GM-CSF

    Metastatic Renal Cell Carcinoma

    Enrollment
    339
    Start
    Dec 2010
    Primary Completion
    Jul 2015
    Completion
    Jul 2015
    NCT01265901
  • Phase 3
    Recruiting

    SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

    IMA203, nivolumab plus relatlimab

    Melanoma, Cutaneous Malignant, Mucosal Melanoma

    Enrollment
    450
    Start
    Jan 2025
    Primary Completion
    Jan 2028est.
    Completion
    Aug 2032est.
    NCT06743126
  • Phase 2
    Completed

    IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease

    Endoxana, IMA901, Leukine, IMA901 and Leukine

    Renal Cell Carcinoma

    Enrollment
    68
    Start
    May 2007
    Primary Completion
    Aug 2009
    Completion
    Aug 2009
    NCT00523159
  • Phase 1/2
    Completed

    IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101)

    Endoxana, Leukine, IMA910, Endoxana, Leukine, IMA910, Aldara

    Colorectal Carcinoma

    Enrollment
    92
    Start
    Jun 2008
    Primary Completion
    Jan 2011
    Completion
    May 2013
    NCT00785122
  • Phase 1/2
    Recruiting

    ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

    IMA203 Product, IMA203 product- flat dose

    Refractory Cancer, Recurrent Cancer +2

    Enrollment
    375
    Start
    May 2019
    Primary Completion
    Dec 2028est.READOUT
    Completion
    Jun 2032est.
    NCT03686124
  • Phase 1/2
    Recruiting

    IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors

    IMA402, IMA402 and checkpoint inhibitor

    Refractory Cancer, Recurrent Cancer +2

    Enrollment
    400
    Start
    Aug 2023
    Primary Completion
    Sep 2027est.READOUT
    Completion
    Sep 2027est.
    NCT05958121
  • Phase 1
    Terminated

    Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma

    Cyclophosphamide, IMA950 plus GM-CSF

    Glioblastoma

    Enrollment
    6
    Start
    Aug 2011
    Primary Completion
    Apr 2014
    Completion
    Apr 2014
    NCT01403285
  • Phase 1
    Completed

    GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients

    APVAC1 vaccine plus Poly-ICLC and GM-CSF, APVAC2 vaccine plus Poly-ICLC and GM-CSF

    Glioblastoma

    Enrollment
    16
    Start
    Oct 2014
    Primary Completion
    Jun 2018
    Completion
    Jun 2018
    NCT02149225
  • Phase 1
    Completed

    ACTolog in Patients With Solid Cancers

    Fludarabine, Cyclophosphamide

    Cancer, Solid Tumor

    Enrollment
    38
    Start
    Jun 2017
    Primary Completion
    Sep 2021
    Completion
    Sep 2021
    NCT02876510
  • Phase 1
    Completed

    TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)

    IMA201 Product

    Solid Tumor, Cancer +2

    Enrollment
    7
    Start
    Dec 2018
    Primary Completion
    Apr 2023
    Completion
    Sep 2023
    NCT03247309
  • Phase 1
    Completed

    TCR-engineered T Cells in Solid Tumors: IMA202-101

    IMA202 Product

    Solid Tumor, Adult, Refractory Cancer +2

    Enrollment
    16
    Start
    May 2019
    Primary Completion
    Jun 2022
    Completion
    Mar 2023
    NCT03441100
  • Phase 1
    Active, not recruiting

    IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor

    IMA401 (Phase Ia), Pembrolizumab (Phase Ia)

    Refractory Cancer, Recurrent Cancer +2

    Enrollment
    95
    Start
    May 2022
    Primary Completion
    Mar 2026
    Completion
    Dec 2029est.
    NCT05359445
  • Phase 1
    Recruiting

    ACTengine® IMA203 Combined With mRNA-4203

    IMA203, mRNA-4203

    Cutaneous Melanoma, Synovial Sarcoma

    Enrollment
    15
    Start
    Jul 2025
    Primary Completion
    Aug 2029est.
    Completion
    Aug 2029est.
    NCT06946225
  • Observational
    Completed

    Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling

    -

    Refractory Cancer, Recurrent Cancer +2

    Enrollment
    242
    Start
    Feb 2019
    Primary Completion
    Nov 2022
    Completion
    Nov 2022
    NCT03760952
Search ClinicalTrials.gov for “Immatics”